Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
IDx
January 22, 2013
Biotech still relying on friends for financing in 2012
August 24, 2012
Bristol-Myers setback another blow to hep C field
April 24, 2012
EP Vantage interview - Idenix tries to play catch-up in torrid hep C race
April 02, 2009
InterMune tops small cap gainers in first quarter of 2009
February 09, 2009
Idenix should be able to keep the good news flowing
August 07, 2008
Companies on the way to being 2008's winners and losers - US focus
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
November 29, 2021
Biopharma Quarterly Round Up (Q3 2021)
November 16, 2021
Covid Round Up (2021)
Editor's Picks
November 22, 2021
The bubble bursts for biotech stocks
November 08, 2021
Ash 2021 preview – as competition grows Autolus monetises
November 23, 2021
Ash 2021 late-breakers enable neat comparisons
November 04, 2021
What Novartis could buy with its windfall
November 16, 2021
Fate buries bad data and moves on
